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Abstract 
Purpose/Background:  The purpose of this quality improvement (QI) project was to increase 
Hepatitis C Virus (HCV) screening and identification through the implementation of universal 
screening for HCV with a Medical Assistant (MA) workflow as provider prompt.  This QI 
project evaluated the effectiveness of universal HCV screening in a federally qualified health 
center (FQHC), community health center (CHC), patient centered medical home serving 
primarily Medicaid, Medicare and uninsured patients.  HCV is a major cause of chronic liver 
disease throughout the world.  It now causes more deaths than any other infectious disease in the 
United States (US).  Costs associated with its treatment are significant and increasing.  
Therefore, early identification through screening and referral to treatment are essential in 
preventing the spread of the disease and reducing disease related morbidity and mortality. 
Methods:  Implementation of universal screening for HCV through an MA driven workflow to 
identify the need for screening and as a provider prompt. 
Results:  The number of HCV at-risk patients screened increased from 1,144 to 1,393, (x2 =  
7.96, p = .0048), representing 21.8% increase in the eight weeks post implementation.  The 
screening rate for all clinic patients increased from 27.1% to 32.2% (x2 = 26.598, p < . 00001).  
Additionally, referrals to HCV treatment increased from 314 to 442 (x2 = 5.507, p = .0189), 
representing a 40.8% increase. 
Conclusion:   This MA driven universal HCV screening workflow demonstrated the 
effectiveness of a simple, cost-effective practice change in improving the identification of HCV 
and referral to treatment.   
 
Keywords: hepatitis C, screening, referral, linkage to care, primary care 
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Increasing the Identification of Hepatitis C and Referral to Treatment in Primary Care Through a 
Medical Assistant Driven Workflow 
Hepatitis C Virus (HCV) infection is a major cause of chronic liver disease in the United 
States (US) and throughout the world (Coyle & Kwakwa, 2016; Heil et al., 2018).  HCV is 
frequently categorized as either acute or chronic.  For most individuals, infection with HCV 
results in a chronic lifelong illness if left untreated (Centers for Disease Control and Prevention 
[CDC], 2018).  It is estimated that at least 2.4 million individuals in the US are living with HCV 
with infection rates increasing due to the national opioid crisis (CDC, 2018; Oregon Health 
Authority [OHA], 2017).  Moreover, most individuals with HCV are unaware of their infection 
as they remain asymptomatic until advanced liver disease occurs (Coyle & Kwakwa, 2016; Ford 
et al., 2018).  Early identification of the disease through screening is essential to preventing the 
spread of the disease and the referral of individuals to effective treatment to reduce costs to the 
healthcare system and save lives.  The financial costs associated with chronic HCV to the 
healthcare system are significant and increasing.  In 2011, the lifetime cost of care for an 
individual with chronic HCV was $64,490 while the US spent $6.5 billion on HCV care that year 
(Razavi et al., 2013).  Deaths from HCV reached record high in 2014, with 19,659 individuals 
dying from HCV in the US (Ly, Hughes, Jiles, & Holmberg, 2016).  HCV now causes more 
deaths than any other infections disease in the US (Ly et al., 2016). 
Early identification, referral to effective treatment and quality care are key in fighting the 
HCV epidemic (Department of Health of Health and Human Services [DHHS], 2017).  Current 
HCV screening recommendations from the CDC include: 1) the baby boomer cohort (adults born 
between 1945 and 1965); 2) current intravenous drug users; 3) individuals with any history of 
injection drug use; 4) individuals with medical conditions which include a history of receiving 
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clotting factors before 1987, long-term hemodialysis, long term alanine aminotransferase levels 
(ALT), and human immunodeficiency virus (HIV) infection; 5) prior recipients of blood 
transfusions or organ transplants; and 6) individuals with a recognized exposure to HCV (CDC, 
2015).  
A quality improvement (QI) project to increase the screening rates for HCV took place at 
a clinic which is a designated healthcare for the homeless clinic, a federally qualified health 
center (FQHC), community health center (CHC), and patient centered medical home located in 
Portland, Oregon serving approximately 5,000 Medicaid, Medicare and uninsured patients 
annually (Central City Concern [CCC], 2016).  HCV positive patients are able to receive their 
care within the clinic as there is an embedded HCV treatment program.  
Clinical Problem 
HCV is the most commonly reported blood born virus in both Oregon and the US (OHA, 
2017).  Furthermore, both chronic HCV and HCV mortality rates for Oregon are over twice that 
of the national average (OHA, 2017).  Oregon has the third highest chronic HCV rate in the 
nation and the second highest mortality rate (HepVu, n.d.; OHA, 2017).  In the US, baby 
boomers, minorities, injection drug users, individuals living in households with annual incomes 
less than $25,000 and those without a high school education are disproportionately affected by 
HCV (Coyle & Kwakwa, 2016).  As the clinic serves those at the highest risk for HCV in the 
community, a robust screening program is essential to help stop the spread of HCV while 
ensuring access to treatment and potential cure to minimize the long-term health effects of 
chronic HCV such as cirrhosis, liver failure and hepatocellular carcinoma (HCC).   
Prior to this project, HCV screening at the clinic was ordered at provider discretion.  
Providers receive annual HCV education covering CDC screening recommendations, treatment 
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recommendations, and how to refer patients to HCV treatment program in the clinic.  It was the 
general expectation that those at risk were screened and referred to treatment if appropriate, 
however there was no supporting policy or practice guideline.  Additionally, there was no 
systematic method to ensure screening for at risk patients such as a flag in the electronic health 
record (EHR), or through a chart review by the Medical Assistant (MA).  Despite knowledgeable 
providers and the availability to refer patients to HCV treatment within the clinic, the lack of a 
standardized process to ensure HCV screening resulted in a gap in screening those at risk for 
HCV.  Analysis of baseline data demonstrated only 53% (1,144 of 2,157) of at-risk patients 
being screened for HCV.  Furthermore, the determination of screening rates for at-risk patients is 
limited by EHR reporting.  EHR reporting defines those at risk as patients in the baby boomer 
cohort and patients with opiate use disorders.  When looking at the entire clinic patient 
population, only 27% (1,144 of 4,227) of patients are screened for HCV.  Due to the 
demographic of patients served by the clinic, patients are disproportionately more likely to be at 
risk of HCV than the general US public.  Therefore, effective screening, diagnosis and referral to 
treatment is essential in managing the long-term health needs of the patients as well as helping 
prevent further spread of HCV.  
Additionally, in working with the HCV program team, clinic care team managers (CTM) 
and MA a lack of standardization and training delivering HCV results to patients was identified.  
Baseline data analysis along with team member interviews demonstrated that the clinic had 
opportunities to improve screening rates for all clinic patients, increase referrals of HCV positive 
patients to treatment, to standardize the result notification process by ensuring the most 
appropriate team members were providing patients with their results and were trained to do so. 
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Through stakeholder engagement, review of current clinic practices and analysis of 
baseline HCV data, the project team concluded that the QI project would focus on achieving the 
following goals: (1) increase HCV screening of clinic patients; (2) increase referral to HCV 




A literature review was conducted searching CINAHL and MEDLINE was conducted 
using the search terms: hepatitis C, screening, and primary care with the Boolean connector and.  
The review was limited to the years 2013 through 2018 with publication in the English language 
only.  A five-year timeframe was chosen due to advances in HCV treatment availability.  
Twenty-two articles were identified in the initial literature search, one additional article was 
found through review of identified articles.  Articles were excluded through review, or title, 
abstract and full-text review resulting in a total of five articles included in this paper.  See 
Appendix A: Literature Review Process.  The literature review demonstrated that screening in 
primary care settings is an effective way to identify HCV (Coyle & Kwakwa, 2016; Ford et al., 
2018; Heil et al., 2018; O'Kelly, Byrne, Naughten, Bergin, & Williams, 2016; Wolffram et al., 
2015).  Furthermore, both risk-factor based and universal HCV testing with linkage to care was 
shown to be effective in FQHCs and CHCs with similar patient populations as OTC (Coyle & 
Kwakwa, 2016; Ford et al., 2018).  See Appendix B: Evidence Table and Appendix C: Synthesis 
Table. 
Theoretical Framework 
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The Quality Implementation Framework (QIF) guided project design and implementation 
(Meyers, Durlak, & Wandersman, 2012).  The QIF was chosen as it provides a structure with 
clearly identified steps to follow and key questions to consider at each step throughout all stages 
of project design, implementation, and evaluation.  Additionally, the QIF provides a large area 
on the assessment and preparation steps to ensure the organization is ready for change and build 
capacity for change, if needed (Meyers et al., 2012).  Lastly, the QIF recognizes that change is a 
cyclical process and allows for bi-directional movement within the framework.  The project 
manager utilized the QIF to ensure key steps were completed during each phase of the project 
design, implementation and evaluation process. 
Stakeholder Engagement 
Clinic providers were surveyed via an online survey distributed through email asking the 
following questions: (1) Do you screen all patients for HCV? (2) If not, how do you determine 
who to screen?, (3) What barriers do you have with screening your patients for HCV?, and (4) 
What would make it easier for you to screen your patients for HCV?.  Providers reported barriers 
to HCV screening including the inability to confirm patient’s HCV screening status, 
unfamiliarity with screening recommendations, unfamiliarity with HCV screening labs, lack of 
time, and other priorities.  Providers frequently have to comb through past medical records to 
find screening results, a time-consuming task.  Additionally, patients frequently recall neither 
past screening nor past behaviors that put them at risk of contracting HCV.  MAs and CTMs 
were interviewed from each care team within the clinic to identify challenges with screening and 
seek feedback as how to improve the process.   
Screening Workflows 
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Based on recommendations from the literature, the HCV team and clinic leadership 
supported moving to a model of universal HCV screening with annual screening for patients with 
ongoing risk factors, such as IV drug use.  The clinic is well situated to have a positive impact on 
HCV rates and treatment outcomes due to its ability to identify HCV in a high-risk population 
group through universal screening and subsequently link them to treatment with the embedded 
HCV program.  While the CDC recommends screening patients in high risk groups, in Oregon 
half of all new HCV infections occur in persons 30 years of age or younger (OHA, 2017).  
Therefore, a universal screening program which offers one-time screening to all clinic patients 
and annual screening for those at continued risk will help to ensure identification of those with 
HCV infection. Through referral of patients who test positive for HCV to the embedded HCV 
program, access to effective care can be ensured, helping to prevent new infections and decrease 
HCV mortality in Oregon.  Clinic providers, CTMs and MAs agreed that adding HCV screening 
status to the clinic’s “huddle prep process” would be an effective method to identify the need for 
screening.   
Huddle Prep Process 
Prior to all patient visits, MAs prepare for the visit by using a huddle prep document.  See 
Appendix D:  HCV Huddle Prep and Resource Initial.  Through this review MAs are able to 
prompt providers for necessary screenings and procedures, such as a capillary blood glucose 
(CBG) or hemoglobin A1C lab draw for diabetics, or HIV screening.  Portions of the necessary 
info for huddle prep pull into the EHR for MAs to review, but other key sections do not, such as 
HCV screening status.  The Huddle Prep document was revised with Clinic Operations Manager 
and MA input to better reflect the actual workflow of MAs as to how they navigate within the 
EHR.  Components of huddle prep were grouped to correspond with where the information is 
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found in the EHR.  See Appendix E:  HCV Huddle Prep and Resource Final.  All clinic MAs 
were trained through an MA staff meeting and individual follow-up by clinic operations 
manager.  Additionally, all MA’s completed a competency assessment of their ability to find the 
information listed on the HPRD in the EHR and provider notification of their findings to allow 
the provider to consider screening if appropriate.   
Result Notification Workflows 
In addition to adjusting the MA workflow to prompt screening, the team standardized the 
result notification process by having health assistants notify patients of negative results, and 
CTMs notify patients of positive results and schedule follow-up care simultaneously.  See 
Appendix F:  Result Notification Process.  CTMs were trained on the positive result notification 
process and HCV counseling by the project coordinator at a team meeting using 
recommendations form the CDC and the Harm Reduction Coalition (CDC, n.d.; Ellendon, 2003).   
Project Implementation Timeline 
 Project development utilizing provider, MA and CTM interviews along with huddle prep 
form revisions and trials occurred in September and October of 2018.  The project was proposed 
and approved by the HCV program team in early November 2018.  CTM training on the new 
HCV result notification process was completed in November of 2018.  MA training and 
competency validation on the revised huddle prep process was completed in December 2018.  
The revised huddle prep process using the new huddle prep document was implemented mid-
December 2018.  See Appendix D:  HCV Huddle Prep and Resource Final. 
Data Collection and Evaluation 
Both process and outcomes measures were tracked to measure efficacy of the project.  
Process measures included MA and CTM training completion rates.  Outcome measures tracked 
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were screening rate of at-risk patients, screening rate of all clinic patients and number of referrals 
to HCV treatment.  Training and competency completion rates were gathered upon 
implementation by the project manager and clinic operations manager using competency 
validation forms.  Eight weeks post implementation, HCV screening and referral numbers were 
gathered and compared to baseline data.  Due to reporting challenges the total number of 
screenings and referrals were tracked and compared to the baseline data, rather than using 
screening and referral rates over separate timeframes.  A chi square analysis was conducted to 
determine the association between the new screening workflow and the increase in HCV 
screening for both at risk and all clinic patients.  Chi square analysis was completed using Social 
Science Statistics (Stangroom, 2019).  
Ethical Considerations 
 Institutional Review Board (IRB) approval was sought and granted for this project by the 
University of Portland IRB committee.  Informed consent to allow their training and competency 
data to be included in the project outcomes was reviewed with MAs and CTMs to include their 
competency and training data in the results of this project.  Patients maintained the right to refuse 
HCV screening and/or referral to treatment.  All project team members were free from relevant 
conflicts of interest. 
Results 
Project outcomes were tracked using a metric tracker table.  See Appendix G:  Metric 
Tracker for more detail.  All 19 clinic MAs competed the huddle prep training and competency 
validations and all six clinic CTMs completed the HCV counseling training.  The number of 
active patients, defined as patients who saw a provider at least once in the last two years, 
increased during the project timeframe from 4,227 to 4,332, an increase of 2.2%.  Furthermore, 
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the number of patients at risk for HCV at the clinic increased from 2,157 to 2,436, representing a 
12.9% increase (x2= 23.30 p < .00001).  The number of at-risk patients screened increased from 
1,144 to 1,393, representing 21.77% increase (x2 = 7.96, p < .004787).  The screening rate for all 
clinic patients increased from 27.06% to 32.16% (x 2= 26.60, p < .00001).  Additionally, 
referrals to HCV treatment increased from 314 to 442 (x2 = 5.51, p = .0189), representing a 
40.8% increase.  The screening rate of all clinic patients increased more than the rate of HCV at-
risk patients, and 18.9% increase as compared to a 7.8% increase.  
Discussion 
These findings suggest that the MA driven workflow to prompt provider consideration of 
the need for HCV screening using a model of universal screening was successful in increasing 
screening for both patients identified as at-risk for HCV and those who were not defined as at 
risk of HCV per CDC recommendations.  The project was optimistically accepted by clinic staff, 
providers, and patients.  As anticipated, the project proved effective in increasing screening for 
both patients identified as at-risk and those who were not, and resulted in an increase in referrals 
to treatment.  Moreover, the rate of increase in referrals rose at a steeper rate than the increase in 
both patients identified at risk, and patients screened, indicating increasing rates of patients 
identified as having HCV.  Screening of patients not traditionally deemed as at-risk is known to 
be effective in identifying chronic HCV as not all patients accurately recall or disclose their at-
risk behaviors (Coyle & Kwakwa, 2016).  The project data is consistent with this finding as the 
total screening rate and referrals to treatment both increased at a higher rate than the HCV at-risk 
screening rate.  
Project Limitations 
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Due to EHR and reporting limitations it was not possible to gather HCV screening, 
identification and referral rates for discontinuous timeframes.  Therefore, all data was analyzed 
beginning February 1, 2017.  February 1, 2017 was chosen as the HCV treatment program began 
at that time resulting in HCV program data available for the total timeframe between February 1, 
2017 and the end of the project data collection timeframe, but not at different intervals.  
Additionally, current EHR reporting does not fully identify all HCV risk factors.  A patient is 
only classified as at-risk if they are in the baby boomer age cohort and if they have “problem” 
history of opiate use disorder.  Therefore, the data analysis does not fully capture all patients at 
risk for HCV.   
Additionally, the data collection timeframe was limited to eight weeks.  During this 
timeframe, HCV screening was fresh in the minds of both MAs and providers.  Ongoing 
evaluation of the project will need to be done by the clinic operations manager and HCV 
program team to continue to assess ongoing effectiveness in increasing HCV screening and 
referrals as a proxy for HCV infection. 
EHR changes to support more rapid identification of HCV screening needs, such as 
clearer identification of risk factors, pulling in HCV screening status to the EHR huddle prep, 
along with improved reporting would have allowed for cleaner data analysis in both the 
gathering of baseline data and post-practice change data.   
Lessons Learned 
 This QI project proceeded smoothly as designed with outcomes as expected.  Utilizing 
the QIF, engaging stakeholders early, identifying potential barriers and developing mitigation 
strategies for those barriers allowed for a successful project which can be sustained utilizing the 
clinic’s existing structures. 
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Conclusion 
HCV screening has been demonstrated to be cost-effective as the early identification and 
treatment of HCV decreases the overall economic burden to the individual and health system 
through the prevention of healthcare related costs and potential disability from liver disease 
(Joshi, 2014).  The current project, intentionally designed to be embedded within current clinic 
structures and workflows at no organizational cost and requires no ongoing additional resources 
in terms of committee structures, time, or staffing for sustainability.  Clinic HCV data will be 
tracked moving forward by the HCV team program coordinator and standard clinic quality 
assurance processes.  The revised MA huddle prep process proved to be a cost-effective means to 
improve HCV identification and linkage to treatment, thus improving the health of clinic patients 
and the community overall.   
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Appendix A:  Literature Review Process 
HEPATITIS C IDENTIFICATION AND TREATMENT REFERRAL 18 























































• Team and 
provider 
training 
• Linkage to 
ongoing 










n = 9035 
 
≥ age 18 pt 
unaware of 














































• 1,888 pt 
tested for 
HCV 















• 101 HCV + 
pt 
• 13 HIV + pt 
 
Strengths: 
• Multiple test sites with 
experience working with 
and tx pt at high risk for 
HCV 
• Free testing 
• Diverse pt sample in 
terms of gender, race  
• Include both pt and 
provider education 
• Used reflexive testing to 
prevent additional lab 
draws 
• Demonstrated efficacy 
and feasibility of opt-out 
HCV and HIV screening 




• No statistical analysis to 
determine if outcomes 
were statistically 
significant changes 
• During study timeframe, 
two test sites moved to 























• 39 HCV + 
pt 




screening for all clients 
due to high rates of 
HCV outside of the baby 
boomer birth cohort and 
known risk factor pts 
 
Applicability: 
• Applicable to OTC due 
to: 
• Similar pt populations 
served 
• All test sites were 





linkage to care and 
availability of tx in 



















in the field 
12 test sites 
comprised of: 
• 6 CHCs 
• 4 FQHCs 




















































• Numerous test sites with 
experience working with 
and tx pt at high risk for 
HCV 
• Free testing 
• Diverse sample in terms 
of gender, race and 
testing site 
• Used rapid HCV ab 
testing in the field  
HEPATITIS C IDENTIFICATION AND TREATMENT REFERRAL 20 













rates of HCV 
infection 
 















































Of the 678 
seropositive pt, 




435 (85%) pt 
with chronic 
HCV had 
linkage to care 
 
Of pt who 
were linked to 












• Did not include total # 
pts outreached to 
• No CI analysis for 
outcomes 
• Included pts who 
already knew HCV 
positive status 
• At the time of the study 
tx restrictions included 
fibrosis levels and active 
IV drug use – these are 
no longer in place  
 
Applicability: 
• Applicable to OTC due 
to: 
• Similar pt populations 
served 
• 10 of the test sites 
were CHC or FQHCs.  






linkage to care and 
availability of tx in 
HEPATITIS C IDENTIFICATION AND TREATMENT REFERRAL 21 
one site, which OTC 
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1063 (89.5%)  




• Simple implementation 
strategy with education 
of all pertinent care team 
members 





testing to all 
adults age 18 
and over who 
presented to 
the sites for 
routine blood 






















• 753 female 
• 453 male 








• pt opt in 
to BBV 
testing 




























opted out of 
BBV testing 
 















• Educational hand outs 
and signs for pts 
• High rate of pts who opt 
in confirms that opt-out 
testing for BBV is viable 
in primary care 
• Adds to limited existing 
literature regarding opt-




• Relatively small study 
with four study sites 
• Limited number of pts 
• Conducted over short 
time-frame (six months) 
 
Applicability: 
• Quite applicable to OTC 
due to: 
• Primary care setting 
• Impoverished area 
• Implementation 
through care team and 
pt education 
• No adjustment to EHR 
needed 
Wolffra



































• Large sample size 
• Large testing uptake 













exam for pt 
who are at 
least 35 and 
is covered by 
insurance 









n = 21,008 
with an avg of 
412 pt at each 
practice 
 




































DV –  



































• HBsAG – 
0.52% 








• 85% of 
HBV + pt 
• 65% of 













• Thorough statistical 
analysis of pt 
demographics and risk 
factors associated with 
HBV and HCV infection 
• First prospective study 
evaluating routine HBV 
and HCV testing in 
primary care in 
Germany 
• Identified a higher 
disease burden than had 
been previously 








• Sample size likely didn’t 
include a representative 
number of high-risk 
patients 
• Data on study 




• Applicable to OTC due 
to: 
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• OTC’s patient 
population contains 
patients identified at 
high risk with this 
study 
• Demonstrates ability 
to complete routine 
HCV and HBV testing 
in a primary care 




Notes: % = percent, + = positive, ab = antibody, ALT = alanine aminotransferase, BBV = blood borne virus, CF = conceptual 
framework, CHC = community health center, CI = confidence interval, DV = dependent variable, EHR, electronic health record, 
FQHC = federally qualified health center, IV= independent variable, HBsAG = hepatitis B surface antigen, HBV = hepatitis B virus, 
HCV = hepatis C virus, HIV = human immunodeficiency virus, MA = medical assistant, NYC = New York City, New York, USA, pt 
= patient, SEP = syringe exchange programs, TF = Theoretical framework, tx = treatment 
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Coyle, et al. 













n = 9035 
 
≥ age 18 pt 
unaware of 









of MA driven 
routine HCV 
and opt-out 
HIV testing as 
part of primary 
care visits 
HCV Screening ⇑ 
HIV Screening ⇑⇑ 
 
HCV Diagnosis ⇑⇑ 
HIV Diagnosis ⇑ 
 
HCV Linkage to Care ⇑⇑ 
HIV Linkage to Care ⇑ 
 
Universal screening for HCV/HIV as part 
of routine primary care with opportunity 
to opt out  
Level 4 




Pts served by 
6 CHCs, 4 
FQHCs, and 






n = 4751 











to care and tx 
HCV ab + ⇑⇑⇑⇑ 
 
HCV infection confirmation ⇑⇑⇑ 
 
HCV linkage to care ⇑⇑ 
 
HCV tx initiated ⇑ 
 
Universal screening for HCV with 
availability of co-located care navigation, 
and HCV tx 
Level 4 
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Heil, et al.,  




70 in 11 
family 
practices in 2 
known HCV 

















invitation to pts 
between age 40 
and 70 to come 
in for free 
HBV and HCV 
testing on one 
of three testing 
days.   
 







HBV/HCV test uptake ⇑⇑⇑ 
 
HCV Diagnosis ⇑ 
 
HBV Diagnosis ⇑⇑ 
 
Birth cohort testing in addition to risk 
factor prevalence for HBV and HCV 
 
Suggested that testing with routine blood 
work would be more effective than having 


























HCV, and HIV 
screening to all 




BBV opt in to testing ⇑⇑ 
 
HBV Diagnosis ⇑ 
 
HCV Diagnosis ⇑ 
 
HIV Diagnosis   
 


















testing in the 
HBV Screening ⇑ 
 
HCV Screening ⇑ 
 
Level 4 
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n = 21,008 
with an avg 
of 412 pt at 
each practice 
 






















risk factors for 
HBV and HCV 
HBV Diagnosis ⇑⇑ 
 
HCV Diagnosis ⇑ 
 
Include HBV and HCV screening as part 
of routine primary care visits with the 
ability to opt-out 
 
 
Notes:  ab = antibody, BBV, blood-borne virus, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, HCV = hepatis C 
virus, HIV = human immunodeficiency virus, MA = medical assistant, NYC = New York City, New York, USA, PCP = primary care 
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Appendix D:  HCV Huddle Prep and Resource Initial 
Test frequency Male Female Diabetic 
 
50-74 18-50 65+ smoker 
SBIRT Initial visit and annual x x      
PHQ 3  x x      
PHQ 9 Initial visit and when PHQ 3 is + x x      
CBG  x x x     
A1C Controlled q 6 months 
Uncontrolled q 3 months 
x x x     
Foot exam Annual x x x     
UA urine dip Annual x x x     
Eye referral Annual x x x     
Flu vaccine Annual x x      
Pneumococcal  One dose x x    x x 
Pap Q 3 years   x   24-64   
Mammogram Q 2 years  x  x    
Colonoscopy Once (unless abnormal) x x  x    
Fit kit annual x x  x    
TSH  Annual if normal, q 6 m if 
abnormal 
       
TDaP Q 10 years x x      
Last pain Rx/last 
UDS? Evaluate refill 
potential (28 day) 
 x x      
Pain medication 
orders 
 x x      
Open orders  x x      
Effective 
contraceptive use 
Annually and q visit if not on 
problem/med list 
 x   x   
Hep C Once and prn risk factors x x x x x x  
HIV Once and annually with risk 
factors 
x x  x x x  
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Appendix E:  HCV Huddle Prep and Resource Final 
Task/Test Frequency Male Female Diabetic 
 
50-74 18-50 65+ smoker Opiate 
RX/Use 
Print provider schedule          
Reason for appointment Every visit x x       
Pop ups/behavior agreements Every visit x x       
Interpreter Needed Every Visit x x       
VACCINES:          
Flu vaccine Annual x x       
Pneumococcal  One dose x x x   x x  
TDaP Q 10 years x x       
CENTRICITY HUDDLE 
INFO: 
         
Open orders Every visit x x       
Hep C test Once and annually with risk 
factors 
x x       
SBIRT Initial visit and annual x x       
A1C Controlled q 6 months 
Uncontrolled q 3 months 
x x x      
Foot exam Annual x x x      
Urine microalbumin/creat Annual x x x      
Eye referral Annual x x x      
Pap Q 5 years   x   24-64    
Mammogram Q 2 years  x  x     
Colonoscopy Once (unless abnormal) x x  x     
Fit kit Annual x x  x     
Problem/Med List:          
Injections/LAI due Every visit x x       
CBG Every visit x x x      
Effective contraceptive 
use** 
Annually or with each visit 
if not on problem/med list 
 x   x    
Dx of COPD:  oxygen level Every visit x x       
LABS:          
Last UDS  Every visit x x      x 
HIV test Once and annually with risk 
factors 
x x       
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Appendix F:  Result Notification Process 
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0 100%  
CTM training 
completion rate 
0 100%  
Total Number of 
Clinic Patients 




2157 2436 12.9% 
 
Patients Not 
Identified as HCV 
At-Risk 
2070 1896 -8.4% 
 





53.0% 57.2% 7.8% 
Total Clinic HCV 
Screening Rate 
27.1% 32.2% 18.9% 
Referrals to HCV 
Treatment 
314 442 40.8% 
 
 
 
